Figure 2
From: Multifunctional Nanotherapeutics for the Treatment of neuroAIDS in Drug Abusers
(A) Development of latent HA model; (B) Dose optimization of different LRA agents; (C) Effects of latency reversing agents on provirus quiescence in HA populations (14 dpi), latent HIV cells were treated with optimized dose of (a) Bryostatin: 1 nm; (b) Vorinostat: 1 µM; (c) Romidepsin: 10 nm; (d) Disulphiram: 5 µM; (e) PMA: 5 nm (positive control) (i) single agent treatment (ii) combination treatment and analyzed for HIV-1 expression for 48 hrs in comparison to untreated controls. Results demonstrate differential effects of LRAs on latent HIV-1 in HA populations. Data are from one infection experiment for each latent cell population, with columns indicating mean values for each time point. Standard errors are shown for the mean of triplicate samples.
